Duodenoscope Lawsuits in 2026: Superbug Infections and Olympus Scope Claims

A duodenoscope is a flexible endoscope used in ERCP procedures, and its complex moving parts make it notoriously hard to disinfect. People who developed antibiotic-resistant infections such as CRE after a scope procedure may have a product liability claim against makers like Olympus, especially where records document contamination even when hospitals followed the cleaning instructions.

Key Facts

  • From 2013 through 2014, the FDA received 75 multi-drug resistance alerts involving about 135 U.S. patients tied to possible transmission from reprocessed duodenoscopes (schmidtlaw.com).
  • In an October 2025 device correction, Olympus reported 2 deaths and 5 serious injuries in 2024–October 2025 potentially related to the TJF-Q190V duodenoscope (schmidtlaw.com).
  • On April 5, 2022, the FDA urged hospitals to abandon reusable duodenoscopes after studies found 6.6 percent still carried high-concern organisms after cleaning, versus 0.5 percent of scopes with disposable components (aboutlawsuits.com).
  • A December 2024 FDA Class I recall of Olympus's MAJ-891 plug followed 120 patient injuries and one death linked to trapped biomaterial (torhoermanlaw.com).
  • In 2018, Olympus pleaded guilty to failing to report duodenoscope-related infections, agreeing to $85 million in criminal penalties: an $80 million fine plus $5 million in forfeiture (aboutlawsuits.com).

Why Duodenoscopes Are So Hard to Clean

A duodenoscope is used in ERCP, short for endoscopic retrograde cholangiopancreatography, which treats blockages in the bile and pancreatic ducts. Unlike a standard endoscope, it has a movable piece at its tip called the forceps elevator, a tiny lever that redirects instruments into the ducts. That elevator and its narrow channels create microscopic crevices where bacteria can survive even after the hospital performs the manufacturer's recommended reprocessing. The organism most associated with these outbreaks is CRE, carbapenem-resistant Enterobacterales, a superbug family resistant to many antibiotics. Once in a patient's bloodstream, CRE can cause sepsis, a life-threatening immune response, and infections may not produce symptoms for days or weeks after the procedure, which is one reason victims sometimes fail to connect their hospitalization to a scope exam they had weeks earlier.

The Regulatory Timeline That Strengthened Claims

The litigation story is inseparable from the regulatory record. In 2015, the FDA warned that duodenoscopes contain small moving parts and hard-to-reach areas where contamination may persist despite recommended disinfection, then ordered Olympus, Fujifilm, and Pentax to study contamination rates. In 2018, warning letters followed the manufacturers' failure to provide sufficient data, and December post-market results showed scopes still testing positive after cleaning. In 2019, the FDA recommended facilities move away from older duodenoscopes with fixed endcaps toward easier-to-clean designs. Enforcement continued: a June 2025 FDA import alert targeted 58 Olympus device models made in Japan; an October 2025 Urgent Field Safety Notice for the TJF-Q190V, TJF-Q290V, and TJF-Q170V admitted prior reprocessing materials required updates and mandated 10X magnification inspection of the tip; and an October 2025 device correction cited continued reports of positive cultures and infections with the TJF-Q190V. Cases filed in 2024 and 2025 involve newer-generation scopes Olympus marketed as safer than the original TJF-Q180V, and if discovery shows even the updated designs remained defective, the company's central defense collapses. This paper trail decides device litigation again and again, from the Philips CPAP recall to pressure cooker explosion cases.

What Makes a Lawsuit Viable in 2026

Not every infection after an ERCP becomes a lawsuit. Attorneys look for four things. First, a documented ERCP or duodenoscopy at a facility that used an implicated scope model, with the procedure date in the medical records. Second, a serious infection within a plausible window afterward, with positive cultures identifying an organism consistent with scope transmission. Third, evidence of real harm: extended hospitalization, intensive care, organ injury, lasting disability, or death. Fourth, a legal theory connecting the manufacturer to the harm, usually product liability alleging a design defect in the elevator mechanism or inadequate reprocessing instructions, plus failure to warn. Discovery in active cases targets internal company documents, FDA communications, hospital infection reports, scope tracking records, and engineering assessments of the elevator channel. With no multidistrict litigation consolidating federal cases, claims are filed individually, each needing proof of infection timing, culture results, causation, and damages.

How Claims Are Usually Filed and Paid

Most injury attorneys accept these cases on a contingency basis, meaning the client pays no fee unless the case results in a recovery. Compensation varies widely by case, and most settlements are confidential. A case's value turns on injury severity, medical costs, lost income, and the strength of the causation evidence. Cases resolve through settlement, mediation, or trial, often over one to three years of reviewing device records, expert reports, and internal documents. Video explainers such as Problem Solved on YouTube walk through how product liability evidence is assembled. Practical point: request your complete hospital records, including the ERCP report naming the scope model and serial number if available, plus every culture and lab result.

Who Benefits From This — and Who Does Not

The people who benefit most are patients who had an ERCP, then developed a documented resistant infection with positive cultures shortly afterward, and families who lost someone under those circumstances. A second group: patients treated with newer-generation scopes such as the TJF-Q190V, because the 2024 and 2025 regulatory actions give their claims fresh evidentiary weight even though the devices were marketed as improved. Our Abilify compulsive-behavior claims show the same failure-to-warn analysis at work.

A lawsuit is not the right answer for everyone. If the infection was mild, resolved quickly without hospitalization, and left no lasting effects, damages are usually too small to justify litigation. Patients whose cultures identified ordinary, antibiotic-sensitive bacteria are harder cases, since the claims depend on resistant organisms tied to scope contamination. And if the infection clearly originated from another source, causation against the scope maker becomes very difficult. An honest attorney will say so during the first evaluation.

This article provides general information only and is not legal or medical advice. Product liability law is complex and varies by state; consult a qualified attorney about your situation.

Frequently Asked Questions

Who benefits most from a duodenoscope infection lawsuit?

Patients who had an ERCP and then developed a documented resistant infection benefit most, as do families who lost someone in those circumstances. Claims involving newer scopes such as the TJF-Q190V carry extra weight after the 2024 and 2025 FDA actions.

Who does not benefit from filing a duodenoscope claim?

People whose infection was mild, treated quickly, and left no lasting effects usually gain little, since damages are too small to justify litigation. Cases are also weak when cultures showed ordinary rather than resistant bacteria.

How do I start a duodenoscope lawsuit claim?

First, request your complete hospital records, including the ERCP report with the scope model and serial number, plus every culture and lab result. Second, write down your symptom timeline. Third, consult a product liability attorney experienced with medical devices, who will evaluate the records before deciding whether to file.

What is CRE and why is it called a superbug?

CRE stands for carbapenem-resistant Enterobacterales, bacteria resistant to many of the strongest antibiotics. It is called a superbug because infections resist treatment and can progress to sepsis, organ failure, or death.

How long do I have to file a duodenoscope lawsuit?

Each state sets its own filing deadline, and some states apply a discovery rule that starts the clock when the victim reasonably learned the infection was linked to the scope. Preserve evidence and speak with an attorney promptly.

Watch on YouTube

Problem Solved on YouTube